• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

促性腺激素释放激素激动剂治疗的子宫肌瘤女性子宫体积缩小的预测因素

Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist.

作者信息

Friedman A J, Daly M, Juneau-Norcross M, Rein M S

机构信息

Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts 02115.

出版信息

Fertil Steril. 1992 Aug;58(2):413-5.

PMID:1633911
Abstract

A retrospective analysis of 104 women with leiomyomata uteri treated with LA for at least 12 weeks demonstrated a negative correlation between the percent reduction in uterine volume and serum E2 concentration at treatment week 12. The patient's age, height, or pretreatment uterine volume were not correlated with the degree of uterine shrinkage.

摘要

一项对104例接受激光消融(LA)治疗至少12周的子宫肌瘤女性患者的回顾性分析表明,在治疗第12周时,子宫体积减少百分比与血清雌二醇(E2)浓度之间呈负相关。患者的年龄、身高或治疗前子宫体积与子宫缩小程度无关。

相似文献

1
Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist.促性腺激素释放激素激动剂治疗的子宫肌瘤女性子宫体积缩小的预测因素
Fertil Steril. 1992 Aug;58(2):413-5.
2
Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist.
Fertil Steril. 1987 Oct;48(4):560-4.
3
Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo.
Fertil Steril. 1990 Feb;53(2):250-3. doi: 10.1016/s0015-0282(16)53276-2.
4
Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women.低剂量醋酸亮丙瑞林微球治疗日本女性子宫平滑肌瘤的疗效
Fertil Steril. 1992 Jul;58(1):66-71. doi: 10.1016/s0015-0282(16)55138-3.
5
A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.一项针对子宫平滑肌瘤女性的促性腺激素释放激素激动剂联合雌激素 - 孕激素或孕激素“反加”方案的前瞻性随机试验。
J Clin Endocrinol Metab. 1993 Jun;76(6):1439-45. doi: 10.1210/jcem.76.6.8501148.
6
Gonadotropin-releasing hormone agonist use before hysterectomy.子宫切除术前使用促性腺激素释放激素激动剂。
Am J Obstet Gynecol. 1994 Jun;170(6):1744-8; discussion 1748-51.
7
Evaluation of leuprolide acetate treatment on histopathology of uterine myomata.醋酸亮丙瑞林治疗对子宫肌瘤组织病理学的评估。
Fertil Steril. 1994 Apr;61(4):622-6.
8
Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.促性腺激素释放激素激动剂治疗子宫平滑肌瘤的疗效:长期随访
Fertil Steril. 1989 Jun;51(6):951-6. doi: 10.1016/s0015-0282(16)60724-0.
9
Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).促性腺激素释放激素激动剂治疗对子宫肌瘤及t(12;14)的缩小作用
Int J Oncol. 2002 Feb;20(2):279-83.
10
Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.用促黄体生成素释放激素激动剂治疗子宫平滑肌瘤:特定围绝经期女性非手术治疗的可能性
Fertil Steril. 1991 May;55(5):900-5. doi: 10.1016/s0015-0282(16)54296-4.

引用本文的文献

1
Gonadotrophin-releasing hormone agonists. A guide to use and selection.促性腺激素释放激素激动剂。使用与选择指南。
Drugs. 1994 Jul;48(1):41-58. doi: 10.2165/00003495-199448010-00005.